TB-500 research, identity and evidence limits
TB-500 requires exact identity checking. Analytical papers identify an acetylated seven-residue thymosin beta-4 fragment; full-length thymosin beta-4 studies do not automatically apply to that fragment.
Identity and formulation
The identified fragment is Ac-LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. Full-length thymosin beta-4 is a different material.
A seller may use TB-500 inconsistently. Neither the short name nor a paper about full-length beta-4 establishes the composition of the product offered.
What the studies show
The directly matched fragment literature reviewed here is largely analytical and preclinical. It establishes identity and metabolism in particular experiments, not successful human tendon or muscle repair. Studies of full-length beta-4, engineered tandem proteins or delivery systems must be labeled separately.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Identification of acetylated thymosin beta-4 fragment in TB-500
Chemical identification and analytical-method work Reading scope: PubMed abstract |
The investigators identified Ac-LKKTETQ in the examined TB-500 preparation and characterized an analytical approach. | This identifies the studied material, not every product using the name or any clinical benefit. |
| TB-500 metabolites and fibroblast wound-healing assays
In-vitro systems, rat metabolism and fibroblast experiments Reading scope: PubMed abstract |
The authors reported that a particular metabolite, rather than the parent fragment, showed significant wound-healing activity in their assay. | An in-vitro wound assay and rat metabolite profile do not establish healing in patients. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Detecting a peptide after administration tells researchers about exposure. It does not show that an injury healed faster or that treatment was safe.
A report on full-length beta-4 can inform a related biological question, but sequence, metabolism and formulation differences prevent silently transferring the outcome to the acetylated fragment.
Safety context
FDA’s current page places the beta-4 fragment among nominations withdrawn by nominators and describes limited human safety information and potential route-dependent immunogenicity concerns. Withdrawal from that nomination category is not product approval or evidence of safety.
Study exposure and units
Do not apply full-length beta-4 exposure schedules or animal fragment doses to an unspecified TB-500 product. Parent compound and metabolite concentrations also describe different analytes.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Require the sequence, acetylation status and expected molecular mass. The report must distinguish full-length beta-4 from Ac-LKKTETQ and identify which one was measured.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Is TB-500 always full-length thymosin beta-4?
No. The analytical papers summarized here identify the shorter acetylated fragment. The actual sequence on a product record must settle the question.
Does a metabolite’s cell-assay result prove TB-500 repairs tendons?
No. It is a narrow preclinical result involving a particular assay and does not establish a human injury outcome.
Does category removal mean FDA approved it?
No. The cited change concerns withdrawal of a compounding nomination, not approval of a drug product.
Sources
- Identification of acetylated thymosin beta-4 fragment in TB-500 (PubMed abstract)
- TB-500 metabolites and fibroblast wound-healing assays (PubMed abstract)
- FDA bulk-substance safety considerations (Official primary page, relevant sections)
- FDA nominated bulk substances, April 22, 2026 (Official primary page, relevant sections)